BioInformant

Your Global Leader in Stem Cell Market Research

Home » exosomes

Exosomes: Company Spotlights from “A” to “Z”

By 4 Comments

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 22,143 scientific articles published about exosomes and 253 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]

List of Exosome Companies: Tiny Packages, Enormous Potential

By 2 Comments

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. [Read more…]

Taking EV characterization to the next level with ONI’s Nanoimager

By Leave a Comment

Extracellular vesicles (EVs) are known for their role in facilitating wide range of intercellular communication such as regulation of the immune response and stem cells differentiation.

What is an extra-cellular vesicle?

EVs are membrane-enclosed particles ranging in size from 30nm to 300nm and their characteristic depend on the cell type releasing them. Often they will carry cargo of active molecules like RNA, DNA, proteins, metabolites and lipids. Moreover, EVs can be found in most biological fluids with the ability to cross biological barriers, and in the case of pathological conditions, the composition of the cargo will be distinctive to the disease. Altogether, these features have led to intense research into the potential role of EVs for diagnostics, biomarkers and as vehicles for drug delivery. [Read more…]

Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

By Leave a Comment

  • Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome
  • 60-patient trial to be conducted nationally at ambulatory infusion sites

AUSTIN, Texas, June 9, 2021 – Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that it has received FDA approval to initiate a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFlo™ in the treatment of Post-Acute COVID-19 Syndrome. This trial is Direct Biologics’ second approved IND, and it represents the first IND ever approved by FDA for the use of extracellular vesicles (EVs) to treat Post-Acute COVID-19 syndrome, Chronic Post-COVID-19 syndrome, or any post-viral syndrome. [Read more…]

BioInformant's World-Class Clients